#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Diffuse large B-cell lymphoma recurrent Von Hippel-Lindau disease Marginal zone lymphoma Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Philadelphia positive chronic myeloid leukaemia Scleroderma associated digital ulcer Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Immunodeficiency common variable Sexually transmitted disease Follicle centre lymphoma follicular grade I, II – III Pulmonary fibrosis Hormone-dependent prostate cancer Hyperadrenocorticism Anti-HLA antibody test positive Liver abscess More trials…

    Learn about Rare Diseases

    Friedreich’s ataxia Marginal zone lymphoma refractory – Diagnostics KBG syndrome – Basic Information Retinoblastoma – Trials in Disease Pemphigus Andersen-Tawil syndrome – Basic Information Synovial sarcoma metastatic – Diagnostics Lymphatic malformation – Treatment Antisynthetase syndrome – Trials in Disease Langerhans’ cell histiocytosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ataluren Sodium Zirconium Cyclosilicate TALADEGIB Clascoterone Abbv-668 Dapagliflozin Propanediol Ixazomib ALLERGEN EXTRACTS L-SERINE Ecopipam Hydrochloride Levamlodipine Succinate Eptinezumab Censavudine Menotrophin Desvenlafaxine Benzoate MEGESTROL ACETATE Vixarelimab Amsacrine Grwd5769 Histidine More therapies…

    Learn about Your Condition

    Measles Oesophageal adenocarcinoma Infantile apnoea Glioblastoma Autoimmune hepatitis Notalgia paraesthetica Anal cancer stage II Oesophageal disorder Obesity Cancer fatigue Alcohol use disorder Alveolar bone defect Liposarcoma metastatic Epithelioid sarcoma Arthroscopy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

    Recruiting

    3 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Nivolumab
    • Relatlimab
    Austria Belgium Czechia Finland France Germany +5

  • Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma refractory
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Belgium France Germany Italy Portugal

  • Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ORG-129
    Austria Belgium Czechia Denmark France Germany +4

  • Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Deupirfenidone
    • Pirfenidone
    Belgium Czechia Denmark France Germany Greece +6

  • Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Belzupacap Sarotalocan
    Austria Belgium Czechia France Germany Italy +2

  • Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

    Not yet recruiting

    2 1 1
    Austria Belgium Germany Italy Poland Romania +2

  • Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Ixazomib Citrate
    • Methotrexate Sodium
    • Sirolimus
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Optic ischaemic neuropathy
    Investigated Drugs:
    • Cenegermin
    Belgium Denmark France Germany Hungary Italy +3

  • A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Hereditary haemorrhagic telangiectasia
    Belgium Bulgaria France Germany Hungary Italy +3

  • First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

    Not yet recruiting

    3 1
    Investigated Drugs:
    • (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
    Austria Belgium Czechia Denmark France Germany +6
Previous Page
1 … 26 27 28 29 30 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!